Recruiting

CRIPB-13-002Evaluation of Vaginal Milieu: Proteins, Cytokines, and Microbiology in Asymptomatic and Symptomatic Women

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This observational study aims to determine the types of cytokines present in the vagina of healthy women and those with vulvodynia, recurrent fungal and bacterial vaginosis, and preterm labor, to understand the vaginal environment in these different conditions.

What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Urogenital Diseases+14

+ Genital Diseases

+ Bacterial Infections and Mycoses

From 21 to 75 Years
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: April 2013
See protocol details

Summary

Principal SponsorTexas Tech University Health Sciences Center
Study ContactAilena R Mulkey, RNMore contacts
Last updated: December 18, 2025
Sourced from a government-validated database.Claim as a partner

Study start date: April 1, 2013

Actual date on which the first participant was enrolled.

Our approach specifically targets the evaluation of the proteins and cytokines present and the bacteriological analysis of the microflora in the vaginal milieu. Conjectures: An initial insult in the vagina (possibly involving a bacterial, viral or fungal organism or their products) causes modifications in the vaginal milieu The vaginal milieu responds to the insult by developing an inflammatory reaction characterized by cytokine and protein production Long lasting or repetitive insults maintain biochemical changes in the vaginal milieu producing a reaction, chemical irritation or micro flora alteration by changes in proteins and/or abnormal protein production Those changes eventually result in hypersensitivity, irritation, burning, and pain manifested in patients with vulvodynia. And those changes may also result in the recurrence of fungal or bacterial infections Those changes may also contribute to initiate the cascade of premature events conducting to cervical effacement and dilation observed in preterm labor The conjectures will be investigated by using a multidisciplinary approach including: microbiology, proteomics and cytokines evaluation of the vaginal milieu. Specifically we will be comparing an asymptomatic female population to serve as a baseline to patients affected by vulvodynia, recurrent fungal or bacterial vaginosis and/or pregnancy. This is a prospective, descriptive study of about 550 women age 12 to 75 years. There will be four groups: 1) Asymptomatic healthy women, 2) Women being seen for any gynecological vulvovaginal condition, and 3) Pregnant women who are asymptomatic and healthy, and 4) Pregnant women have any gynecological vulvovaginal condition. We will evaluate the following: Types of cytokines normally present in women and in patients with vulvodynia, recurrent fungal and bacterial vaginosis and preterm labor Normal microbiology flora in women and variations present in the vaginal milieu in these patients The presence of normal and atypical proteins in the vaginal milieu of healthy women and patients with vulvodynia, recurrent fungal and bacterial vaginosis and preterm labor Informed consent will be obtained and documented for participation in the study Comprehensive history assessment of environmental factors, topical vulvovaginal issues and co morbid conditions as defined in the exclusion criteria. Pelvic examination to obtain two samples via cotton swabs for proteomics, cytokines, vaginal lactobacillus from vaginal secretions. A. Swab procedure: The cotton swabs (2) will be introduced only in the middle vagina, one at the time, no other areas will be sampled. B. Swab processing One swab will be placed in a special room temperature solution. This de-identified swab will be mailed for Lactobacillus. The second de-identified swab is to be place in 2 separated micro-containers in Liquid Nitrogen Containers (one for cytokines and one for Proteomics). When 50 samples are completed they will be processed at TTUHSC Permian Basin campus, with the Proteomics testing being done in Lubbock. Therefore, there are 3 samples, each processed differently. Data will be recorded in a confidential manner with no personal identifiers, only an assigned study subject number. As such, the de-identified data may serve as a database for additional studies. The computer used will belong to TTUHSC and be password protected, access limited to only authorized personnel. Consent forms will be stored separately from the study data in the research office.

Principal SponsorTexas Tech University Health Sciences Center
Study ContactAilena R Mulkey, RNMore contacts
Last updated: December 18, 2025
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

550 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 21 to 75 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesBacterial Infections and MycosesBacterial InfectionsFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleInfectionsObstetric Labor ComplicationsPregnancy ComplicationsVaginal DiseasesVaginitisVulvar DiseasesFemale Urogenital DiseasesObstetric Labor, PrematureMycosesVaginosis, BacterialVulvodynia

Criteria

Inclusion Criteria: All patients willing to participate, and give informed consent, and Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination. Non-pregnant women ages 21 to 75 years being evaluated for any gynecological vulvovaginal condition. Pregnant women ages 21 to 75 years who are both asymptomatic and healthy Pregnant women ages 21 to 75 who have any gynecological vulvovaginal condition Exclusion Criteria: Asymptomatic patients ages < 21 or > 75, or symptomatic patients ages < 21 or > 75 years. Patients diagnosed with cancer or having any medical condition that is not under control including: diabetes mellitus, hypertension, collagen disease, hemoglobinopathy, renal insufficiency, depression, anxiety, psychosis and panic attacks Patients unable to follow the protocol or unwilling to participate

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

4 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

TTUHSC Permian Basin

Midland, United StatesOpen TTUHSC Permian Basin in Google Maps
Recruiting
One Study Center